The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8. Under the deal, ...

"Imagine defunding penicillin research in 1943 because of rare reactions. Absurd, right?" Dr. Jerome Adams wrote on X.

Pima County health officials say fall vaccine supplies remain steady despite changes in federal research funding.

So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using that Nobel Prize-winning technology to try to develop vaccines and treatments against a ...

CSL Seqirus was one of the drugmakers the federal government listed this week as having its mRNA-related work cut. In an ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

At that time, the administration of the National Institutes of Health, which is responsible for biomedical research, had also requested a list of all NIH- funded research projects dealing with mRNA ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac $740 million plus royalties to settle US legal disputes over Covid-19 vaccines, ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

GSK said it would receive $370 million as part of a U.S. patent settlement between CureVac and BioNTech related to messenger mRNA-based Covid-19 vaccines.